These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19144760)

  • 21. Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
    Krimholtz MJ; Karalliedde J; Thomas S; Bilous R; Viberti G
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S42-7. PubMed ID: 15938033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial.
    Li P; Chen Y; Liu J; Hong J; Deng Y; Yang F; Jin X; Gao J; Li J; Fang H; Liu G; Shi L; Du J; Li Y; Yan M; Wen Y; Yang W
    PLoS One; 2015; 10(5):e0126027. PubMed ID: 25938778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
    Taheri S; Asim M; Al Malki H; Fituri O; Suthanthiran M; August P;
    Trials; 2018 Apr; 19(1):230. PubMed ID: 29665833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
    Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG
    Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.
    Alkhalaf A; Klooster A; van Oeveren W; Achenbach U; Kleefstra N; Slingerland RJ; Mijnhout GS; Bilo HJ; Gans RO; Navis GJ; Bakker SJ
    Diabetes Care; 2010 Jul; 33(7):1598-601. PubMed ID: 20413516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
    Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
    Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
    Saklayen MG; Gyebi LK; Tasosa J; Yap J
    J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
    Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
    Zhao XM; Zhang Y; He XH; Chen HD; Wang ZF; Guo J; Wang XM; Gao ZZ; Wang JP; Liu W; Zhao LH; Tong XL
    Trials; 2018 Mar; 19(1):200. PubMed ID: 29587863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of spironolactone on nephron function in patients with diabetic nephropathy.
    Ustundag A; Tugrul A; Ustundag S; Sut N; Demirkan B
    Ren Fail; 2008; 30(10):982-91. PubMed ID: 19016150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
    Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ; Song JH; Suh JH; Lee SW; Kim GA
    Yonsei Med J; 2003 Jun; 44(3):463-72. PubMed ID: 12833584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
    Dieterle W; Mann J
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):668-74. PubMed ID: 17190377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.
    Smolander J; Vogt B; Maillard M; Zweiacker C; Littke T; Hengelage T; Burnier M
    Clin Pharmacol Ther; 2009 Jun; 85(6):628-34. PubMed ID: 19279566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.